FAKTOR OPTIONSSCHEIN - ASTRAZENECA ADR | Real-time Bid/Ask 10:17:30 2024-07-17 am EDT | ||
| 3.93 EUR / 3.96 EUR | -8.89% |
|
| Current month | -0.69% | ||
| 1 month | +13.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 4.28 | -1.15% |
| 24-07-16 | 4.33 | +8.52% |
| 24-07-15 | 3.99 | -9.32% |
| 24-07-12 | 4.4 | -2.00% |
| 24-07-11 | 4.49 | -9.48% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 02:28 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | UBS |
| WKN | UM5VD2 |
| ISIN | DE000UM5VD29 |
| Date issued | 2024-05-14 |
| Strike | 91.69 $ |
| Maturity | Unlimited |
| Parity | 2.87 : 1 |
| Emission price | 5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.27 € |
|---|---|
| Lowest since issue | 3.58 € |
| Spread | 0.03 € |
| Spread % | 0.74% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
156.8
USD
Average target price
177.6
USD
Spread / Average Target
+13.31%
- Stock Market
- Certificates
- Certificat
